|Over a month ago|
Marker Therapeutics reports Q1 EPS , consensus (14c) » 16:2505/1205/12/21
At March 31, Marker had…
At March 31, Marker had cash and cash equivalents of $64.5M. The company believes that its existing cash and cash equivalents will fund its operating expenses and capital expenditure requirements into Q1 2023. "We had a productive first quarter supported by our recently completed financing, strengthening our overall cash position and enabling continued growth and expansion of our Multi-TAA pipeline," said CEO Peter Hoang. "In addition, we continue to make strong progress on both the clinical and manufacturing fronts. In March, we dosed the first patient in the safety lead-in portion of our Phase 2 trial in post-transplant acute myeloid leukemia, or AML, and continue to activate clinical sites. In parallel, we continue to optimize the MT-401 cell therapy manufacturing process, which we believe could result in an increase in the number of T cells available for patient administration-among other benefits-as we prepare to operationalize our new in-house cGMP facility in the first half of the year."
Marker Therapeutics to present mTAA-specific T cell manufacturing data » 19:4904/2704/27/21
Marker Therapeutics announced that it will present data detailing a new robotics technology to aid in multi-tumor-associated antigen (mTAA)-specific T cell therapy manufacturing at the upcoming American Society of Gene & Cell Therapy Annual Meeting, taking place virtually May 11-14, 2021. The data will be presented by lead author Anastasiya Smith, Ph.D. The presentation details how the robotic assistant prototype, co-designed by Marker Therapeutics and ABB Robotics, could in the future be integrated in a standard biosafety cabinet to collaborate with a human operator during mTAA-specific T cell manufacturing. The researchers found that the robotic assistant prototype was more precise and accurate than human operators in pipetting liquid and was more consistent in the number of cycles performed over a 1-hour test period, while the human operator's performance deteriorated over time. The authors conclude that the future combination of process simplification with robotic automation may be able to address some of the challenges associated with cell therapy and make this therapy readily available to a larger patient population.
|Over a quarter ago|
Marker Therapeutics initiated with an Overweight at Piper Sandler » 04:5503/2503/25/21
Piper Sandler analyst…
Piper Sandler analyst Joseph Catanzaro initiated coverage of Marker Therapeutics with an Overweight rating and $6 price target. The analyst views the company's MultiTAA platform as a "highly differentiated" T-cell therapy that offers "multiple potential distinct advantages" at both clinical efficacy and safety, as well as manufacturability. With a potentially registrational Phase II acute myeloid leukemia trial now enrolling, Catanzaro sees "significant opportunity" for Marker shares to appreciate as the MultiTAA platform is advanced through the clinic.
Fly Intel: Top five analyst initiations » 09:3003/1903/19/21
BYND, NEBC, APD, MRKR, AEVA
Catch up on today's…
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Beyond Meat (BYND) initiated at Stephens with an Overweight rating. 2. Rover (NEBC) initiated at DA Davidson with a Buy rating. 3. Air Products (APD) initiated with an Outperform rating at Cowen. 4. Marker Therapeutics (MRKR) initiated with an Overweight rating at Cantor Fitzgerald. 5. Aeva Technologies (AEVA) started with an Outperform rating at Oppenheimer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
Fly Intel: Pre-market Movers » 09:0103/1903/19/21
NKE, FDX, IDRA, MRKR, SKLZ, FSR
Check out this morning's…
Marker Therapeutics up 20% at $2.17 per share after insider transaction 16:5403/1803/18/21
Marker Therapeutics director buys 1.7M shares of common stock » 16:4903/1803/18/21
In a regulatory filing,…
In a regulatory filing, Marker Therapeutics disclosed that its director John Wilson bought 1.7M shares on March 16th in a total transaction size of $3.0M, boosting his stake by 28%.
Cantor Fitzgerald starts 'undervalued' Marker Therapeutics at Overweight » 16:1703/1803/18/21
As previously reported,…
As previously reported, Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Marker Therapeutics with an Overweight rating and $6 price target. The company is focusing on novel T-cell immunotherapies based on the Multiple Tumor-Associated Antigen, or "MultiTAA," therapy platform and she believes shares are undervalued given the potential for its technology to target multiple antigens, allow for a safer profile, and increase durability, Kluska tells investors.
Marker Therapeutics initiated with an Overweight at Cantor Fitzgerald » 16:0403/1803/18/21
Cantor Fitzgerald analyst…
Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Marker Therapeutics with an Overweight rating and $6 price target.
Fly Intel: Pre-market Movers » 08:5303/1203/12/21
LB, CFRX, NVAX, WISA, ITRM, DSSI, OCUL, POSH, RIDE, MRKR, POWW, DS
Check out this morning's…